Evidence map›Paper›PMID 30592390›Full record

Trial reportStem cells translational medicine2019

Umbilical Cord-Derived Mesenchymal Stromal Cells (MSCs) for Knee Osteoarthritis: Repeated MSC Dosing Is Superior to a Single MSC Dose and to Hyaluronic Acid in a Controlled Randomized Phase I/II Trial.

Jose Matas, Mario Orrego, Diego Amenabar, Catalina Infante, Rafael Tapia-Limonchi, Maria Ignacia Cadiz, Francisca Alcayaga-Miranda, Paz L González, Emilio Muse, Maroun Khoury and 2 more

Registry-linked trialOpen access · goldAbstract readClinical Trial, Phase IClinical Trial, Phase IIRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Stem cells translational medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05751564 (Enabling Advanced Medical Therapy in the Americas), which is not on this map. Cited by 240 papers, 17 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
240citing papers in PubMed, 17 pooled it
17.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05751564 phase2unknown statusnot on this mapstarted 2023, after this paper: background citation

Enabling Advanced Medical Therapy in the Americas: A Pilot Study to Validate a "Ready-to-use" Intra-articular Formulation of Mesenchymal Stromal Cells, Aiming Toward an Effective and Scalable Treatment for Symptomatic Knee Osteoarthritis

TypeinterventionalSponsorUniversidad de los Andes, ChileRan2023 to 2025Enrolled60ConditionsOsteo Arthritis KneeArms"Ready to inject" Umbilical cord-derived Mesenchymal Stromal Cell (MSC) product, Resuspended Umbilical cord-derived Mesenchymal Stromal Cell (MSC) product
3 · Its place in the literature

Who cites it

240 citing papers in PubMed, 17 syntheses or guidelines pooled it, 406 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Stem cell injections for osteoarthritis of the knee.The Cochrane database of systematic reviews · 2025
    Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Pooled it
  13. Pooled it
  14. Pooled it
  15. Pooled it
  16. Pooled it
  17. Pooled it
  18. SPOT: An Early Detection Tool for Predicting Pain Trajectories Following Intra-Articular Injections.Journal of orthopaedic research : official publication of the Orthopaedic Research Society · 2026
    Trial
  19. Trial
  20. Trial

180 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 2 countries.

Jose MatasDepartment of Orthopedic Surgery, Universidad de los Andes, Santiago, Chile.
Mario OrregoDepartment of Orthopedic Surgery, Universidad de los Andes, Santiago, Chile.
Diego AmenabarDepartment of Orthopedic Surgery, Universidad de los Andes, Santiago, Chile.
Catalina InfanteCells for Cells & Consorcio Regenero, Santiago, Chile.
Rafael Tapia-LimonchiCells for Cells & Consorcio Regenero, Santiago, Chile.
Maria Ignacia CadizCells for Cells & Consorcio Regenero, Santiago, Chile.
Francisca Alcayaga-MirandaCells for Cells & Consorcio Regenero, Santiago, Chile.
Paz L GonzálezLaboratory of Nano-Regenerative Medicine, Universidad de los Andes, Santiago, Chile.
Emilio MuseDepartment of Radiology, Clínica Universidad de los Andes, Santiago, Chile.
Maroun KhouryCells for Cells & Consorcio Regenero, Santiago, Chile.
Fernando E FigueroaProgram for Translational Research in Cell Therapy, Universidad de los Andes, Santiago, Chile.ORCID 0000-0002-9387-094X
Francisco EspinozaCells for Cells & Consorcio Regenero, Santiago, Chile.ORCID 0000-0002-1607-8641
Universidad de Los Andes, Chile · CLCells Therapy (Poland) · PL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Knee osteoarthritis (OA) is a leading cause of pain and disability. Although conventional treatments show modest benefits, pilot and phase I/II trials with bone marrow (BM) and adipose-derived (AD) mesenchymal stromal cells (MSCs) point to the feasibility, safety, and occurrence of clinical and structural improvement in focal or diffuse disease. This study aimed to assess the safety and efficacy of the intra-articular injection of single or repeated umbilical cord-derived (UC) MSCs in knee OA. UC-MSCs were cultured in an International Organization for Standardization 9001:2015 certified Good Manufacturing Practice-type Laboratory. Patients with symptomatic knee OA were randomized to receive hyaluronic acid at baseline and 6 months (HA, n = 8), single-dose (20 × 10

Indexed as

AdultBone MarrowDouble-Blind MethodFemaleHumansHyaluronic AcidInjections, Intra-ArticularMaleMesenchymal Stem CellsMesenchymal Stem Cell TransplantationMiddle AgedOsteoarthritis, KneeUmbilical CordVisual Analog ScaleHyaluronic AcidDisabilityKneeMesenchymal stromal cellsOsteoarthritisPain

Identifiers

PMID30592390
PMCPMC6392367
OpenAlexW2907679499

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.